House Subcommittee Postpones Pediatric Antidepressant Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
A conflict caused the Energy & Commerce/Oversight Subcommittee to postpone a July 20 hearing on clinical trial publication and disclosure issues. Results from a new study evaluating suicidal behavior in patients taking SSRIs versus tricyclic antidepressants could be a topic of discussion during the rescheduled hearing.
You may also be interested in...
Antidepressant Safety Concerns Not Impacting Forest's SSRI Sales
Publicity surrounding the safety of antidepressants in adult and pediatric patients is not having an impact on Forest's sales of Lexapro and Celexa, President Kenneth Goodman said during a July 20 conference call
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.